转移性结直肠癌(mCRC)的管理:现实世界的建议。

IF 0.6 Q4 ONCOLOGY
South Asian Journal of Cancer Pub Date : 2024-12-11 eCollection Date: 2024-10-01 DOI:10.1055/s-0044-1791689
Purvish M Parikh, Ankur Bahl, Gopal Sharma, Raja Pramanik, Jyoti Wadhwa, Peush Bajpai, Sunny Jandyal, A P Dubey, Aditya Sarin, Subash Chandra Dadhich, Avinash P Saklani, Ashok Kumar, Abhijit Chandra, Saumitra Rawat, C Selvasekar, Shyam Aggarwal
{"title":"转移性结直肠癌(mCRC)的管理:现实世界的建议。","authors":"Purvish M Parikh, Ankur Bahl, Gopal Sharma, Raja Pramanik, Jyoti Wadhwa, Peush Bajpai, Sunny Jandyal, A P Dubey, Aditya Sarin, Subash Chandra Dadhich, Avinash P Saklani, Ashok Kumar, Abhijit Chandra, Saumitra Rawat, C Selvasekar, Shyam Aggarwal","doi":"10.1055/s-0044-1791689","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Metastatic CRC is considered as a heterogenous disease. Its management is therefore complex and dynamic. In order the give a ready reference to community oncologists, we developed this real world recommendations.</p><p><strong>Methods: </strong>A group of experts with academic background and real world experience in mCRC got together. We reviewed the current literature and the insights gained from our real world experience. Based on the same we put together these recommendations.</p><p><strong>Recommendations results: </strong>Molecular testing should be done wherever possible. Most of these patients will be treated with a palliative approach. Doublet chemotherapy is a long-standing standard of care. Triplet therapy may be offered where a more aggressive approach is indicated. Combination with anti -vascular endothelial growth factor antibodies and/or anti EGFR antibodies is also considered standard. In the first-line setting, pembrolizumab can be used for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumours; Left and right sided tumours are distinct entities. Combination of chemotherapy and targeted therapy is used as per individual patient and tumour characteristics.Oligometastatic disease can be approached with potentially curative intent. Cytoreductive surgery plus chemotherapy can be offered to selected patients with peritoneal only metastases. Stereotactic body radiation therapy can be used as local therapy for patients with oligometastatic liver only disease who cannot be taken up for surgery. New strategies include induction-maintenance chemotherapy and perioperative chemotherapy. All drugs/ regimen included as standard of care in the first line can also be used in subsequent lines. Specific targetable driver mutation tumours can be treated accordingly with their complementary biological therapy.</p><p><strong>Conclusion: </strong>Multidisciplinary team management and shared decision making are possible when patient and caregivers choose to become active participants.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"13 4","pages":"287-295"},"PeriodicalIF":0.6000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888815/pdf/","citationCount":"0","resultStr":"{\"title\":\"Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations.\",\"authors\":\"Purvish M Parikh, Ankur Bahl, Gopal Sharma, Raja Pramanik, Jyoti Wadhwa, Peush Bajpai, Sunny Jandyal, A P Dubey, Aditya Sarin, Subash Chandra Dadhich, Avinash P Saklani, Ashok Kumar, Abhijit Chandra, Saumitra Rawat, C Selvasekar, Shyam Aggarwal\",\"doi\":\"10.1055/s-0044-1791689\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Metastatic CRC is considered as a heterogenous disease. Its management is therefore complex and dynamic. In order the give a ready reference to community oncologists, we developed this real world recommendations.</p><p><strong>Methods: </strong>A group of experts with academic background and real world experience in mCRC got together. We reviewed the current literature and the insights gained from our real world experience. Based on the same we put together these recommendations.</p><p><strong>Recommendations results: </strong>Molecular testing should be done wherever possible. Most of these patients will be treated with a palliative approach. Doublet chemotherapy is a long-standing standard of care. Triplet therapy may be offered where a more aggressive approach is indicated. Combination with anti -vascular endothelial growth factor antibodies and/or anti EGFR antibodies is also considered standard. In the first-line setting, pembrolizumab can be used for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumours; Left and right sided tumours are distinct entities. Combination of chemotherapy and targeted therapy is used as per individual patient and tumour characteristics.Oligometastatic disease can be approached with potentially curative intent. Cytoreductive surgery plus chemotherapy can be offered to selected patients with peritoneal only metastases. Stereotactic body radiation therapy can be used as local therapy for patients with oligometastatic liver only disease who cannot be taken up for surgery. New strategies include induction-maintenance chemotherapy and perioperative chemotherapy. All drugs/ regimen included as standard of care in the first line can also be used in subsequent lines. Specific targetable driver mutation tumours can be treated accordingly with their complementary biological therapy.</p><p><strong>Conclusion: </strong>Multidisciplinary team management and shared decision making are possible when patient and caregivers choose to become active participants.</p>\",\"PeriodicalId\":22053,\"journal\":{\"name\":\"South Asian Journal of Cancer\",\"volume\":\"13 4\",\"pages\":\"287-295\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2024-12-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888815/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"South Asian Journal of Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0044-1791689\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0044-1791689","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

转移性结直肠癌被认为是一种异质性疾病。因此,它的管理是复杂和动态的。为了给社区肿瘤学家一个现成的参考,我们开发了这个现实世界的建议。方法:召集一批具有学术背景和实际经验的mCRC专家。我们回顾了当前的文献和从我们的现实世界经验中获得的见解。在此基础上,我们提出了这些建议。建议结果:尽可能进行分子检测。这些患者中的大多数将采用姑息治疗方法。双重化疗是一种长期的治疗标准。三重疗法可提供更积极的方法是指。联合抗血管内皮生长因子抗体和/或抗EGFR抗体也被认为是标准的。在一线治疗中,派姆单抗可用于mCRC和微卫星不稳定性高或缺陷错配修复肿瘤患者;左右两侧肿瘤是不同的实体。化疗和靶向治疗的联合使用是根据每个病人和肿瘤的特点。少转移性疾病可以有潜在的治疗目的。只有腹膜转移的患者可以选择细胞减少手术加化疗。立体定向体放射治疗可作为局部治疗的患者少转移性肝脏疾病不能采取手术。新的策略包括诱导维持化疗和围手术期化疗。所有在一线作为标准治疗的药物/方案也可以在后续一线使用。特异性的可靶向驱动突变肿瘤可以相应的用它们的补充生物疗法治疗。结论:当患者和护理人员选择成为积极的参与者时,多学科团队管理和共同决策是可能的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations.

Introduction: Metastatic CRC is considered as a heterogenous disease. Its management is therefore complex and dynamic. In order the give a ready reference to community oncologists, we developed this real world recommendations.

Methods: A group of experts with academic background and real world experience in mCRC got together. We reviewed the current literature and the insights gained from our real world experience. Based on the same we put together these recommendations.

Recommendations results: Molecular testing should be done wherever possible. Most of these patients will be treated with a palliative approach. Doublet chemotherapy is a long-standing standard of care. Triplet therapy may be offered where a more aggressive approach is indicated. Combination with anti -vascular endothelial growth factor antibodies and/or anti EGFR antibodies is also considered standard. In the first-line setting, pembrolizumab can be used for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumours; Left and right sided tumours are distinct entities. Combination of chemotherapy and targeted therapy is used as per individual patient and tumour characteristics.Oligometastatic disease can be approached with potentially curative intent. Cytoreductive surgery plus chemotherapy can be offered to selected patients with peritoneal only metastases. Stereotactic body radiation therapy can be used as local therapy for patients with oligometastatic liver only disease who cannot be taken up for surgery. New strategies include induction-maintenance chemotherapy and perioperative chemotherapy. All drugs/ regimen included as standard of care in the first line can also be used in subsequent lines. Specific targetable driver mutation tumours can be treated accordingly with their complementary biological therapy.

Conclusion: Multidisciplinary team management and shared decision making are possible when patient and caregivers choose to become active participants.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
80
审稿时长
35 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信